Ironwood Pharmaceuticals Share Holder Equity 2012-2025 | IRWD

Ironwood Pharmaceuticals share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
Ironwood Pharmaceuticals Annual Share Holder Equity
(Millions of US $)
2024 $-301
2023 $-346
2022 $652
2021 $606
2020 $63
2019 $-93
2018 $-196
2017 $10
2016 $67
2015 $95
2014 $89
2013 $38
2012 $144
2011 $110
Ironwood Pharmaceuticals Quarterly Share Holder Equity
(Millions of US $)
2025-09-30 $-264
2025-06-30 $-308
2025-03-31 $-334
2024-12-31 $-301
2024-09-30 $-311
2024-06-30 $-322
2024-03-31 $-331
2023-12-31 $-346
2023-09-30 $-326
2023-06-30 $-347
2023-03-31 $707
2022-12-31 $652
2022-09-30 $591
2022-06-30 $533
2022-03-31 $518
2021-12-31 $606
2021-09-30 $580
2021-06-30 $512
2021-03-31 $110
2020-12-31 $63
2020-09-30 $6
2020-06-30 $-37
2020-03-31 $-72
2019-12-31 $-93
2019-09-30 $-153
2019-06-30 $-219
2019-03-31 $-237
2018-12-31 $-196
2018-09-30 $-197
2018-06-30 $-44
2018-03-31 $-18
2017-12-31 $10
2017-09-30 $-18
2017-06-30 $5
2017-03-31 $30
2016-12-31 $67
2016-09-30 $59
2016-06-30 $81
2016-03-31 $91
2015-12-31 $95
2015-09-30 $100
2015-06-30 $140
2015-03-31 $68
2014-12-31 $89
2014-09-30 $108
2014-06-30 $142
2014-03-31 $189
2013-12-31 $38
2013-09-30 $84
2013-06-30 $139
2013-03-31 $59
2012-12-31 $144
2012-09-30 $182
2012-06-30 $129
2012-03-31 $164
2011-12-31 $110
2011-09-30 $113
2011-06-30 $130
2011-03-31 $145
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.732B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.303B 32.40
Zoetis (ZTS) United States $54.932B 19.66
Takeda Pharmaceutical (TAK) Japan $51.421B 10.49
Daiichi Sankyo, - (DSNKY) Japan $39.630B 19.74
BeOne Medicines - (ONC) Switzerland $37.087B 196.62
Sandoz Group AG (SDZNY) Switzerland $33.939B 0.00
United Therapeutics (UTHR) United States $20.018B 17.62
Merck (MKKGY) Germany $19.496B 12.02
Shionogi (SGIOY) Japan $15.261B 14.02
Neurocrine Biosciences (NBIX) United States $13.200B 31.67
Summit Therapeutics (SMMT) United States $13.140B 0.00
IPSEN (IPSEY) France $13.109B 0.00
Ionis Pharmaceuticals (IONS) United States $12.363B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.394B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.236B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.576B 20.00
Stevanato Group S.p.A (STVN) Italy $5.981B 33.47
Crinetics Pharmaceuticals (CRNX) United States $5.313B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.613B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.216B 20.01
Indivior (INDV) United States $4.068B 16.60
Corcept Therapeutics (CORT) United States $3.653B 39.47
NewAmsterdam Pharma (NAMS) Netherlands $3.589B 0.00
Hypermarcas (HYPMY) Brazil $3.047B 20.91
Centessa Pharmaceuticals (CNTA) United Kingdom $2.984B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.790B 8.90
Ocular Therapeutix (OCUL) United States $2.401B 0.00
Dyne Therapeutics (DYN) United States $2.386B 0.00
Soleno Therapeutics (SLNO) United States $2.282B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.098B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.958B 23.20
Harrow (HROW) United States $1.774B 108.86
Guardian Pharmacy Services (GRDN) United States $1.712B 32.96
Ardelyx (ARDX) United States $1.640B 0.00
Oruka Therapeutics (ORKA) United States $1.617B 0.00
Enliven Therapeutics (ELVN) United States $1.585B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.570B 0.00
Collegium Pharmaceutical (COLL) United States $1.441B 7.14
BioCryst Pharmaceuticals (BCRX) United States $1.404B 83.25
Evotec AG (EVO) Germany $1.282B 0.00
Relay Therapeutics (RLAY) United States $1.274B 0.00
Xeris Biopharma Holdings (XERS) United States $1.248B 0.00
Savara (SVRA) United States $1.184B 0.00
ARS Pharmaceuticals (SPRY) United States $1.051B 0.00
Theravance Biopharma (TBPH) United States $1.014B 42.57
Cronos Group (CRON) Canada $0.967B 0.00
Xencor (XNCR) United States $0.913B 0.00
Nektar Therapeutics (NKTR) United States $0.766B 0.00
KalVista Pharmaceuticals (KALV) United States $0.738B 0.00
Esperion Therapeutics (ESPR) United States $0.727B 0.00
ProKidney (PROK) United States $0.689B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.680B 6.07
Bioventus (BVS) United States $0.656B 13.44
Lexeo Therapeutics (LXEO) United States $0.539B 0.00
Elite Pharmaceuticals (ELTP) United States $0.506B 0.00
Lyell Immunopharma (LYEL) United States $0.505B 0.00
Zevra Therapeutics (ZVRA) United States $0.503B 0.00
Organogenesis (ORGO) United States $0.481B 0.00
Siga Technologies (SIGA) United States $0.471B 6.45
Altimmune (ALT) United States $0.442B 0.00
4D Molecular Therapeutics (FDMT) United States $0.431B 0.00
Nature's Sunshine Products (NATR) United States $0.421B 25.07
Aquestive Therapeutics (AQST) United States $0.404B 0.00
USANA Health Sciences (USNA) United States $0.401B 11.19
Akebia Therapeutics (AKBA) United States $0.361B 0.00
Achieve Life Sciences (ACHV) Canada $0.310B 0.00
Profound Medical (PROF) Canada $0.298B 0.00
Aclaris Therapeutics (ACRS) United States $0.284B 0.00
Avalo Therapeutics (AVTX) United States $0.279B 0.00
Aldeyra Therapeutics (ALDX) United States $0.279B 0.00
Relmada Therapeutics (RLMD) United States $0.274B 0.00
OmniAb (OABI) United States $0.274B 0.00
Heron Therapeutics (HRTX) United States $0.273B 0.00
Fractyl Health (GUTS) United States $0.262B 0.00
Larimar Therapeutics (LRMR) United States $0.259B 0.00
Protara Therapeutics (TARA) United States $0.259B 0.00
Silence Therapeutics (SLN) United Kingdom $0.238B 0.00
Enlivex Therapeutics (ENLV) Israel $0.223B 0.00
Journey Medical (DERM) United States $0.217B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.209B 0.00
Galectin Therapeutics (GALT) United States $0.196B 0.00
Minerva Neurosciences (NERV) United States $0.193B 0.00
Century Therapeutics (IPSC) United States $0.190B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
MediWound (MDWD) Israel $0.180B 0.00
Surrozen (SRZN) United States $0.171B 0.00
AleAnna (ANNA) United States $0.171B 0.00
VAXART, INC (VXRT) United States $0.169B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.146B 0.00
Unicycive Therapeutics (UNCY) United States $0.133B 0.00
Context Therapeutics (CNTX) United States $0.132B 0.00
Incannex Healthcare (IXHL) Australia $0.131B 0.00
Inhibikase Therapeutics (IKT) United States $0.126B 0.00
Avita Medical (RCEL) United States $0.119B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.116B 0.00
Karyopharm Therapeutics (KPTI) United States $0.116B 0.00
Prelude Therapeutics (PRLD) United States $0.114B 0.00
Pyxis Oncology (PYXS) United States $0.110B 0.00
Cardiol Therapeutics (CRDL) Canada $0.105B 0.00
Champions Oncology (CSBR) United States $0.100B 42.41
Cassava Sciences (SAVA) United States $0.099B 0.00
Vivani Medical (VANI) United States $0.093B 0.00
Korro Bio (KRRO) United States $0.083B 0.00
Assertio Holdings (ASRT) United States $0.074B 0.00
Gain Therapeutics (GANX) United States $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.070B 58.13
PolyPid (PYPD) Israel $0.069B 0.00
Dominari Holdings (DOMH) United States $0.069B 0.00
NRx Pharmaceuticals (NRXP) United States $0.067B 0.00
Arch Biopartners (ACHFF) Canada $0.066B 0.00
Rafael Holdings (RFL) United States $0.064B 0.00
Acrivon Therapeutics (ACRV) United States $0.062B 0.00
Metagenomi (MGX) United States $0.062B 0.00
Lipocine (LPCN) United States $0.062B 0.00
PMV Pharmaceuticals (PMVP) United States $0.060B 0.00
ElectroCore (ECOR) United States $0.057B 0.00
Nutriband (NTRB) United States $0.053B 0.00
Lite Strategy (LITS) United States $0.053B 0.00
Telomir Pharmaceuticals (TELO) United States $0.048B 0.00
Talphera (TLPH) United States $0.047B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
Plus Therapeutics (PSTV) United States $0.040B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Kyntra Bio Inc (KYNB) United States $0.037B 0.00
Wellgistics Health (WGRX) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.030B 0.00
Jupiter Neurosciences (JUNS) United States $0.030B 0.00
Natural Alternatives (NAII) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.027B 0.00
TherapeuticsMD (TXMD) United States $0.026B 0.00
Klotho Neurosciences (KLTO) United States $0.024B 0.00
Scienture Holdings (SCNX) United States $0.022B 0.00
Liminatus Pharma (LIMN) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
Vivos Therapeutics (VVOS) United States $0.020B 0.00
Inotiv (NOTV) United States $0.020B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
Traws Pharma (TRAW) United States $0.016B 0.02
Vyome Holdings (HIND) United States $0.016B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Tempest Therapeutics (TPST) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.010B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.010B 0.00
Ainos (AIMD) United States $0.009B 0.00
BioVie (BIVI) United States $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Heatwurx (PCSA) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Decoy Therapeutics Inc (DCOY) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Jaguar Animal Health (JAGX) United States $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.003B 0.00
CDT Equity (CDT) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00